Proteolysis targeting chimera (PROTAC) technology has become a powerful strategy in drug
discovery, especially for undruggable targets/proteins. A typical PROTAC degrader consists …

Novel tissue-agnostic therapeutics targeting driver mutations in tumor cells have been
recently approved by FDA, driven by basket trials that have demonstrated their efficacy and …

The function of the p53 protein is impaired by the overexpression of its negative regulator
murine double minute 2 protein (MDM2) and homologous protein MDMX. Disruption of the …

Simple Summary In human cancer, the major tumor suppressor p53 is often functionally
inactivated through the deregulation of its negative regulators MDM2 and MDM4. The …

In gynecological neoplasms, immunohistochemical (IHC) expression of p53 is generally an
accurate predictor of TP53 mutation status if correctly interpreted by the pathologist …

A significant proportion of meningiomas are clinically aggressive, but there is currently no
effective chemotherapy for meningiomas. An increasing number of studies have been …

The combination of compounds with complementary bioactivities into hybrid molecules is an
emerging concept in drug discovery. In this study, we aimed to synthesize new hybrid …

Inhibition of MDM2/p53 interaction with small-molecule inhibitors stabilizes p53 from MDM2
mediated degradation, which is a promising strategy for the treatment of cancer. In this …

Brain radiation has been medically used to alter the metabolism of cancerous cells and
induce their elimination. Rarely, though, brain radiation has been used to interfere with the …

A wealth of evidence has emerged that there is an association between aging, senescence
and tumorigenesis. Senescence, a biological process by which cells cease to divide and …